Do analysts prefer LTRN or DTSQ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, LTRN or DTSQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.62 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is LTRN or DTSQ more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -368.02% -148.62% DT Cloud Star Acquisition N/A N/A N/A

Do analysts prefer BNR or LTRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer LTRN or KLRS?

Kalaris Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 375.89%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kalaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has preferable valuation and earnings, LTRN or KLRS?

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.62 N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A

Is LTRN or KLRS more profitable?

Kalaris Therapeutics' return on equity of -71.71% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -368.02% -148.62% Kalaris Therapeutics N/A -71.71% -42.95%

Do analysts recommend LTRN or ACRV?

Acrivon Therapeutics has a consensus price target of $13.50, indicating a potential upside of 555.34%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation and earnings, LTRN or ACRV?

Lantern Pharma is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.62 N/A Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A

Is LTRN or ACRV more profitable?

Acrivon Therapeutics' return on equity of -70.14% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -368.02% -148.62% Acrivon Therapeutics N/A -70.14% -61.60%

Do analysts recommend LTRN or ATRA?

Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential downside of 0.31%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Atara Biotherapeutics is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atara Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Lantern Pharma (LTRN) Competitors

$1.87 -0.06 (-3.11%)

As of 04:00 PM Eastern

Compare

LTRN vs. DTSQ, BNR, KLRS, ACRV, and ATRA

Should you buy Lantern Pharma stock or one of its competitors? Lantern Pharma's main competitors and comparable companies include DT Cloud Star Acquisition (DTSQ), Burning Rock Biotech (BNR), Kalaris Therapeutics (KLRS), Acrivon Therapeutics (ACRV), and Atara Biotherapeutics (ATRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lantern Pharma compare to DT Cloud Star Acquisition?

Lantern Pharma (NASDAQ:LTRN) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

DT Cloud Star Acquisition's return on equity of 0.00% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
DT Cloud Star Acquisition	N/A	N/A	N/A

Lantern Pharma has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, DT Cloud Star Acquisition had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 1 mentions for DT Cloud Star Acquisition and 0 mentions for Lantern Pharma. DT Cloud Star Acquisition's average media sentiment score of 1.92 beat Lantern Pharma's score of 0.00 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Lantern Pharma	Neutral
DT Cloud Star Acquisition	Very Positive

28.6% of Lantern Pharma shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by company insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

DT Cloud Star Acquisition beats Lantern Pharma on 6 of the 8 factors compared between the two stocks.

How does Lantern Pharma compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Burning Rock Biotech has higher revenue and earnings than Lantern Pharma. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.47	-$7.92M	-$0.82	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A

Lantern Pharma has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -11.57%. Burning Rock Biotech's return on equity of -10.98% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
Lantern Pharma	N/A	-368.02%	-148.62%

Burning Rock Biotech has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Burning Rock Biotech's average media sentiment score of 0.00 equaled Lantern Pharma'saverage media sentiment score.

Company	Overall Sentiment
Burning Rock Biotech	Neutral
Lantern Pharma	Neutral

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Burning Rock Biotech beats Lantern Pharma on 7 of the 10 factors compared between the two stocks.

How does Lantern Pharma compare to Kalaris Therapeutics?

Lantern Pharma (NASDAQ:LTRN) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Kalaris Therapeutics' return on equity of -71.71% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kalaris Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 375.89%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Kalaris Therapeutics had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 2 mentions for Kalaris Therapeutics and 0 mentions for Lantern Pharma. Kalaris Therapeutics' average media sentiment score of 0.51 beat Lantern Pharma's score of 0.00 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lantern Pharma	Neutral
Kalaris Therapeutics	Positive

Lantern Pharma has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

Summary

Kalaris Therapeutics beats Lantern Pharma on 9 of the 13 factors compared between the two stocks.

How does Lantern Pharma compare to Acrivon Therapeutics?

Lantern Pharma (NASDAQ:LTRN) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Acrivon Therapeutics' return on equity of -70.14% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Acrivon Therapeutics has a consensus price target of $13.50, indicating a potential upside of 555.34%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Acrivon Therapeutics had 3 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Acrivon Therapeutics and 0 mentions for Lantern Pharma. Acrivon Therapeutics' average media sentiment score of 0.63 beat Lantern Pharma's score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lantern Pharma	Neutral
Acrivon Therapeutics	Positive

Lantern Pharma has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Lantern Pharma is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

Summary

Acrivon Therapeutics beats Lantern Pharma on 10 of the 13 factors compared between the two stocks.

How does Lantern Pharma compare to Atara Biotherapeutics?

Lantern Pharma (NASDAQ:LTRN) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential downside of 0.31%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Atara Biotherapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Atara Biotherapeutics' average media sentiment score of 0.95 beat Lantern Pharma's score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lantern Pharma	Neutral
Atara Biotherapeutics	Positive

Atara Biotherapeutics has higher revenue and earnings than Lantern Pharma. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Atara Biotherapeutics	$120.77M	0.79	$32.69M	-$1.18	N/A

Lantern Pharma has a beta of 2.3, suggesting that its stock price is 130% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

Lantern Pharma has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Atara Biotherapeutics' return on equity of -79.12% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Atara Biotherapeutics beats Lantern Pharma on 12 of the 15 factors compared between the two stocks.

Get Lantern Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LTRN vs. The Competition

Export

Metric	Lantern Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.67M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-1.15	12.66	273.28	25.38
Price / Sales	N/A	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	-7.48	16.29	12.89	6.14
Net Income	-$17.12M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-13.43%	-1.37%	-0.33%	-1.47%
1 Month Performance	-28.35%	11.07%	6.51%	2.47%
1 Year Performance	-56.41%	53.71%	25.19%	15.84%

Lantern Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LTRN Lantern Pharma	0.2899 of 5 stars	$1.87 -3.1%	N/A	-52.1%	$24.67M	N/A	N/A	20	Gap Down High Trading Volume
DTSQ DT Cloud Star Acquisition	1.8208 of 5 stars	$11.36 +0.1%	N/A	+8.4%	$101.03M	N/A	N/A	N/A	Positive News Short Interest Decrease
BNR Burning Rock Biotech	0.6238 of 5 stars	$9.22 -2.4%	N/A	+22.0%	$99.40M	$77.16M	N/A	1,390	Gap Up
KLRS Kalaris Therapeutics	2.1867 of 5 stars	$3.92 -3.0%	$18.75 +378.3%	-2.5%	$96.17M	N/A	N/A	110
ACRV Acrivon Therapeutics	3.1782 of 5 stars	$2.07 -1.0%	$13.50 +552.2%	+60.4%	$89.56M	N/A	N/A	58	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LTRN) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantern Pharma (LTRN) Competitors

LTRN vs. DTSQ, BNR, KLRS, ACRV, and ATRA

How does Lantern Pharma compare to DT Cloud Star Acquisition?

Summary

How does Lantern Pharma compare to Burning Rock Biotech?

Summary

How does Lantern Pharma compare to Kalaris Therapeutics?

Summary

How does Lantern Pharma compare to Acrivon Therapeutics?

Summary

How does Lantern Pharma compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lantern Pharma (LTRN) Competitors

LTRN vs. DTSQ, BNR, KLRS, ACRV, and ATRA

How does Lantern Pharma compare to DT Cloud Star Acquisition?

Which has preferable valuation & earnings, LTRN or DTSQ?

Is LTRN or DTSQ more profitable?

Which has more volatility and risk, LTRN or DTSQ?

Do analysts prefer LTRN or DTSQ?

Does the media refer more to LTRN or DTSQ?

Do insiders & institutionals have more ownership in LTRN or DTSQ?

Summary

How does Lantern Pharma compare to Burning Rock Biotech?

Which has stronger earnings and valuation, BNR or LTRN?

Is BNR or LTRN more profitable?

Which has more risk and volatility, BNR or LTRN?

Do analysts prefer BNR or LTRN?

Does the media favor BNR or LTRN?

Do insiders & institutionals believe in BNR or LTRN?

Summary

How does Lantern Pharma compare to Kalaris Therapeutics?

Is LTRN or KLRS more profitable?

Do insiders and institutionals hold more shares of LTRN or KLRS?

Do analysts prefer LTRN or KLRS?

Does the media refer more to LTRN or KLRS?

Which has more volatility and risk, LTRN or KLRS?

Which has preferable valuation and earnings, LTRN or KLRS?

Summary

How does Lantern Pharma compare to Acrivon Therapeutics?

Is LTRN or ACRV more profitable?

Do institutionals & insiders believe in LTRN or ACRV?

Do analysts recommend LTRN or ACRV?

Does the media refer more to LTRN or ACRV?

Which has more risk and volatility, LTRN or ACRV?

Which has preferable valuation and earnings, LTRN or ACRV?

Summary

How does Lantern Pharma compare to Atara Biotherapeutics?

Do analysts recommend LTRN or ATRA?

Does the media refer more to LTRN or ATRA?

Which has stronger earnings & valuation, LTRN or ATRA?

Which has more risk & volatility, LTRN or ATRA?

Is LTRN or ATRA more profitable?

Do insiders & institutionals believe in LTRN or ATRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools